Altered DNA methylation in leukocytes with trisomy 21

PLoS Genetics

Volumn 6, Issue 11, 2010, Pages

  Kerkel, Kristi ^a   Schupf, Nicole ^a,b   Hatta, Kota ^c   Pang, Deborah ^a   Salas, Martha ^a   Kratz, Alexander ^a   Minden, Mark ^d   Murty, Vundavalli ^a   Zigman, Warren B ^b   Mayeux, Richard P ^a   Jenkins, Edmund C ^b   Torkamani, Ali ^e   Schork, Nicholas J ^e   Silverman, Wayne ^f,g   Croy, B Anne ^c   Tycko, Benjamin ^a  

^a NewYork Presbyterian Hospital   (United States)

^b NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^c QUEEN S UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^f KENNEDY KRIEGER INSTITUTE   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; CARNITINE PALMITOYLTRANSFERASE 1B; CARNITINE PALMITOYLTRANSFERASE I; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CYTOPLASM PROTEIN; INITIATION FACTOR 4E; MEMBRANE PROTEIN; PHOSPHOLIPASE D; PHOSPHOLIPASE D6; PROTEIN FAM62C; PROTEIN SH3BP2; SUMO 3 PROTEIN; SYNAPTOTAGMIN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ZETA CHAIN 3; TRANSCRIPTION FACTOR 7; TRANSMEMBRANE PROTEIN 131; UNCLASSIFIED DRUG; AZACITIDINE; HYDROGEN SULFITE; MESSENGER RNA; NERVE PROTEIN; NOD2 PROTEIN, HUMAN; NPDC1 PROTEIN, HUMAN; SULFITE;

ADULT; ARTICLE; CELL MATURATION; CHROMOSOME 21; CONTROLLED STUDY; CPG ISLAND; DNA FINGERPRINTING; DNA METHYLATION; DNA MICROARRAY; DOWN SYNDROME; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE SEQUENCE; GENETIC STABILITY; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; PYROSEQUENCING; T LYMPHOCYTE; TRISOMY 21; VALIDATION PROCESS; AGING; CHILD; DNA SEQUENCE; DRUG EFFECT; GENE EXPRESSION PROFILING; GENETICS; INFANT; LEUKEMIA CELL LINE; LEUKOCYTE; LYMPHOCYTE; METABOLISM; PRESCHOOL CHILD; REPRODUCIBILITY;

ADULT; AGING; AZACITIDINE; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; DOWN SYNDROME; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INFANT; JURKAT CELLS; LEUKOCYTE COUNT; LEUKOCYTES; LYMPHOCYTES; NERVE TISSUE PROTEINS; NOD2 SIGNALING ADAPTOR PROTEIN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; SULFITES;

EID: 78649715229     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1001212     Document Type: Article

References (54)

1. Lejeune J, Gautier M, Turpin R (1959) Study of somatic chromosomes from 9 mongoloid children. C R Hebd Seances Acad Sci 248: 1721-1722.
2. Lejeune J, Turpin R, Gautier M (1959) Mongolism; a chromosomal disease (trisomy). Bull Acad Natl Med 143: 256-265.
3. Wiseman FK, Alford KA, Tybulewicz VL, Fisher EM (2009) Down syndrome-recent progress and future prospects. Hum Mol Genet 18: R75-83.
4. Antonarakis SE, Epstein CJ (2006) The challenge of Down syndrome. Trends Mol Med 12: 473-479.
5. Nespoli L, Burgio GR, Ugazio AG, Maccario R (1993) Immunological features of Down's syndrome: a review. J Intellect Disabil Res 37(Pt 6): 543-551.
6. Karlsson B, Gustafsson J, Hedov G, Ivarsson SA, Anneren G (1998) Thyroid dysfunction in Down's syndrome: relation to age and thyroid autoimmunity. Arch Dis Child 79: 242-245.
7. Du Vivier A, Munro DD (1975) Alopecia areata, autoimmunity, and Down's syndrome. Br Med J 1: 191-192.
8. Gillespie KM, Dix RJ, Williams AJ, Newton R, Robinson ZF, et al. (2006) Islet autoimmunity in children with Down's syndrome. Diabetes 55: 3185-3188.
9. Book L, Hart A, Black J, Feolo M, Zone JJ, et al. (2001) Prevalence and clinical characteristics of celiac disease in Downs syndrome in a US study. Am J Med Genet 98: 70-74.
10. Wachtel TJ, Pueschel SM (1991) Macrocytosis in Down syndrome. Am J Ment Retard 95: 417-420.
11. Rozovski U, Jonish-Grossman A, Bar-Shira A, Ochshorn Y, Goldstein M, et al. (2007) Genome-wide expression analysis of cultured trophoblast with trisomy 21 karyotype. Hum Reprod 22: 2538-2545.
12. Prandini P, Deutsch S, Lyle R, Gagnebin M, Delucinge Vivier C, et al. (2007) Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance. Am J Hum Genet 81: 252-263.
13. Li CM, Guo M, Salas M, Schupf N, Silverman W, et al. (2006) Cell type-specific over-expression of chromosome 21 genes in fibroblasts and fetal hearts with trisomy 21. BMC Med Genet 7: 24.
14. Mao R, Wang X, Spitznagel EL Jr., Frelin LP, Ting JC, et al. (2005) Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart. Genome Biol 6: R107.
15. Giannone S, Strippoli P, Vitale L, Casadei R, Canaider S, et al. (2004) Gene expression profile analysis in human T lymphocytes from patients with Down Syndrome. Ann Hum Genet 68: 546-554.
16. Kerkel K, Spadola A, Yuan E, Kosek J, Jiang L, et al. (2008) Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet 40: 904-908.
17. Issa JP (2003) Age-related epigenetic changes and the immune system. Clin Immunol 109: 103-108.
18. de Hingh YC, van der Vossen PW, Gemen EF, Mulder AB, Hop WC, et al. (2005) Intrinsic abnormalities of lymphocyte counts in children with down syndrome. J Pediatr 147: 744-747.
19. Maccario R, Ugazio AG, Nespoli L, Alberini C, Montagna D, et al. (1984) Lymphocyte subpopulations in Down's syndrome: high percentage of circulating HNK-1+, Leu 2a+ cells. Clin Exp Immunol 57: 220-226.
20. Anneren G, Magnusson CG, Lilja G, Nordvall SL (1992) Abnormal serum IgG subclass pattern in children with Down's syndrome. Arch Dis Child 67: 628-631.
21. Loh RK, Harth SC, Thong YH, Ferrante A (1990) Immunoglobulin G subclass deficiency and predisposition to infection in Down's syndrome. Pediatr Infect Dis J 9: 547-551.
22. Cossarizza A, Ortolani C, Forti E, Montagnani G, Paganelli R, et al. (1991) Agerelated expansion of functionally inefficienT-cells with markers of natural killer activity in Down's syndrome. Blood 77: 1263-1270.
23. Noble RL, Warren RP (1988) Analysis of blood cell populations, plasma zinc and natural killer cell activity in young children with Down's syndrome. J Ment Defic Res 32(Pt 3): 193-201.
24. Mahmoud SA, Lowery-Nordberg M, Chen H, Thurmon T, Ursin S, et al. (2005) Immune defects in subjects with dysmorphic disorders. Allergy Asthma Proc 26: 373-381.
25. Nurmi T, Huttunen K, Lassila O, Henttonen M, Sakkinen A, et al. (1982) Natural killer cell function in trisomy-21 (Down's syndrome). Clin Exp Immunol 47: 735-741.
26. Hanna J, Bechtel P, Zhai Y, Youssef F, McLachlan K, et al. (2004) Novel insights on human NK cells' immunological modalities revealed by gene expression profiling. J Immunol 173: 6547-6563.
27. Tybulewicz VL, Fisher EM (2006) New techniques to understand chromosome dosage: mouse models of aneuploidy. Hum Mol Genet 15 Spec No 2: R103-109.
28. Chango A, Abdennebi-Najar L, Tessier F, Ferre S, Do S, et al. (2006) Quantitative methylation-sensitive arbitrarily primed PCR method to determine differential genomic DNA methylation in Down Syndrome. Biochem Biophys Res Commun 349: 492-496.
29. Jenkins EC, Schupf N, Genovese M, Ye LL, Kapell D, et al. (1997) Increased low-level chromosome 21 mosaicism in older individuals with Down syndrome. Am J Med Genet 68: 147-151.
30. Percy ME, Markovic VD, Dalton AJ, McLachlan DR, Berg JM, et al. (1993) Age-associated chromosome 21 loss in Down syndrome: possible relevance to mosaicism and Alzheimer disease. Am J Med Genet 45: 584-588.
31. Wilson MG, Towner JW, Forsman I (1980) Decreasing mosaicism in Down's syndrome. Clin Genet 17: 335-340.
32. Jablonska B, Ford D, Trisler D, Pessac B (2006) The growth capacity of bone marrow CD34 positive cells in culture is drastically reduced in a murine model of Down syndrome. C R Biol 329: 726-732.
33. Carmichael CL, Majewski IJ, Alexander WS, Metcalf D, Hilton DJ, et al. (2009) Hematopoietic defects in the Ts1Cje mouse model of Down syndrome. Blood 113: 1929-1937.
34. Alford K, Slender A, Vanes L, Li Z, Fisher EM, et al. Perturbed hematopoiesis in the Tc1 mouse model of Down Syndrome. Blood.
35. Tydell CC, David-Fung ES, Moore JE, Rowen L, Taghon T, et al. (2007) Molecular dissection of prethymic progenitor entry into the T lymphocyte developmental pathway. J Immunol 179: 421-438.
36. Held W, Kunz B, Lowin-Kropf B, van de Wetering M, Clevers H (1999) Clonal acquisition of the Ly49A NK cell receptor is dependent on the trans-acting factor TCF-1. Immunity 11: 433-442.
37. Kunz B, Held W (2001) Positive and negative roles of the trans-acting T cell factor-1 for the acquisition of distinct Ly-49 MHC class I receptors by NK cells. J Immunol 166: 6181-6187.
38. Ioannidis V, Kunz B, Tanamachi DM, Scarpellino L, Held W (2003) Initiation and limitation of Ly-49A NK cell receptor acquisition by T cell factor-1. J Immunol 171: 769-775.
39. Guo Y, Maillard I, Chakraborti S, Rothenberg EV, Speck NA (2008) Core binding factors are necessary for natural killer cell development and cooperate with Notch signaling during T-cell specification. Blood 112: 480-492.
40. Rahman MK, Midtling EH, Svingen PA, Xiong Y, Bell MP, Tung J, Smyrk T, Egan LJ, Faubion WA Jr. (2010) The pathogen recognition receptor NOD2 regulates human FOXP3+ T cell survival. J Immunol 184: 7247-7256.
41. Chen G, Dimitriou ID, La Rose J, Ilangumaran S, Yeh WC, Doody G, Turner M, Gommerman J, Rottapel R (2007) The 3BP2 adapter protein is required for optimal B-cell activation and thymus-independent type 2 humoral response. Mol Cell Biol 8: 3109-3122.
42. Mor A, Campi G, Du G, Zheng Y, Foster DA, et al. (2007) The lymphocyte function-associated antigen-1 receptor costimulates plasma membrane Ras via phospholipase D2. Nat Cell Biol 9: 713-719.
43. Mao X, Green JM, Safer B, Lindsten T, Frederickson RM, et al. (1992) Regulation of translation initiation factor gene expression during human T cell activation. J Biol Chem 267: 20444-20450.
44. Murooka TT, Rahbar R, Platanias LC, Fish EN (2008) CCL5-mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR/4EBP1. Blood 111: 4892-4901.
45. Dobreva G, Dambacher J, Grosschedl R (2003) SUMO modification of a novel MAR-binding protein, SATB2, modulates immunoglobulin mu gene expression. Genes Dev 17: 3048-3061.
46. Terui Y, Saad N, Jia S, McKeon F, Yuan J (2004) Dual role of sumoylation in the nuclear localization and transcriptional activation of NFAT1. J Biol Chem 279: 28257-28265.
47. Garaude J, Farras R, Bossis G, Charni S, Piechaczyk M, et al. (2008) SUMOylation regulates the transcriptional activity of JunB in T lymphocytes. J Immunol 180: 5983-5990.
48. Evrard C, Caron S, Rouget P (2004) Functional analysis of the NPDC-1 gene. Gene 343: 153-163.
49. Jiang L, Gonda T, Gamble M, Salas M, Seshan V, et al. (2008) Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Res 68: 9900-9908.
50. Yuan E, Haghighi F, White S, Costa R, McMinn J, et al. (2006) A single nucleotide polymorphism chip-based method for combined genetic and epigenetic profiling: validation in decitabine therapy and tumor/normal comparisons. Cancer Res 66: 3443-3451.
51. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, et al. (2004) DChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 20: 1233-1240.
52. Li LC, Dahiya R (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431.
53. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
54. Hatta K, van den Heuvel MJ, Croy BA (2009) NK cells detect changes in adaptive immunity within mouse decidua from gestation day eight. Placenta 30: 501-506.